Skip to main content

Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.

Publication ,  Journal Article
Mentz, RJ; Buggey, J; Fiuzat, M; Ersbøll, MK; Schulte, PJ; DeVore, AD; Eisenstein, EL; Anstrom, KJ; OʼConnor, CM; Velazquez, EJ
Published in: J Cardiovasc Pharmacol
May 2015

Furosemide has historically been the primary loop diuretic in heart failure patients despite data suggesting potential advantages with torsemide. We used the Duke Echocardiography Lab Database to investigate patients admitted with heart failure to Duke Hospital from 2000 to 2010 who were discharged on either torsemide or furosemide. We described baseline characteristics based on discharge diuretic and assessed the relationship with all-cause mortality through 5 years. Of 4580 patients, 86% (n = 3955) received furosemide and 14% (n = 625) received torsemide. Patients receiving torsemide were more likely to be female and had more comorbidities compared with furosemide-treated patients. Survival was worse in torsemide-treated patients [5-year Kaplan-Meier estimated survival of 41.4% (95% CI: 36.7-46.0) vs. 51.5% (95% CI: 49.8-53.1)]. After risk adjustment, torsemide use was no longer associated with increased mortality (hazard ratio 1.16; 95% CI: 0.98-1.38; P = 0.0864). Prospective trials are needed to investigate the effect of torsemide versus furosemide because of the potential for residual confounding.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Cardiovasc Pharmacol

DOI

EISSN

1533-4023

Publication Date

May 2015

Volume

65

Issue

5

Start / End Page

438 / 443

Location

United States

Related Subject Headings

  • Ultrasonography
  • Treatment Outcome
  • Torsemide
  • Tertiary Care Centers
  • Sulfonamides
  • Sodium Potassium Chloride Symporter Inhibitors
  • Sex Factors
  • Risk Factors
  • Retrospective Studies
  • North Carolina
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mentz, R. J., Buggey, J., Fiuzat, M., Ersbøll, M. K., Schulte, P. J., DeVore, A. D., … Velazquez, E. J. (2015). Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital. J Cardiovasc Pharmacol, 65(5), 438–443. https://doi.org/10.1097/FJC.0000000000000212
Mentz, Robert J., Jonathan Buggey, Mona Fiuzat, Mads K. Ersbøll, Phillip J. Schulte, Adam D. DeVore, Eric L. Eisenstein, Kevin J. Anstrom, Christopher M. OʼConnor, and Eric J. Velazquez. “Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.J Cardiovasc Pharmacol 65, no. 5 (May 2015): 438–43. https://doi.org/10.1097/FJC.0000000000000212.
Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, et al. Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital. J Cardiovasc Pharmacol. 2015 May;65(5):438–43.
Mentz, Robert J., et al. “Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.J Cardiovasc Pharmacol, vol. 65, no. 5, May 2015, pp. 438–43. Pubmed, doi:10.1097/FJC.0000000000000212.
Mentz RJ, Buggey J, Fiuzat M, Ersbøll MK, Schulte PJ, DeVore AD, Eisenstein EL, Anstrom KJ, OʼConnor CM, Velazquez EJ. Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital. J Cardiovasc Pharmacol. 2015 May;65(5):438–443.

Published In

J Cardiovasc Pharmacol

DOI

EISSN

1533-4023

Publication Date

May 2015

Volume

65

Issue

5

Start / End Page

438 / 443

Location

United States

Related Subject Headings

  • Ultrasonography
  • Treatment Outcome
  • Torsemide
  • Tertiary Care Centers
  • Sulfonamides
  • Sodium Potassium Chloride Symporter Inhibitors
  • Sex Factors
  • Risk Factors
  • Retrospective Studies
  • North Carolina